CSF2 and neoplasm: Our studies demonstrated that the insertion of both hTERT tumor specific promoter and GM-CSF transgene have not attenuated the performance of Ad6-hT-GM in vitro and in vivo models: its oncolytic efficacy was comparable with that of Ad6 and Ad5 wild-type control vectors.